Retractable Techs., Inc. v. Becton Dickinson & Co.

919 F.3d 869
CourtCourt of Appeals for the Fifth Circuit
DecidedMarch 26, 2019
Docket17-40960
StatusPublished
Cited by18 cases

This text of 919 F.3d 869 (Retractable Techs., Inc. v. Becton Dickinson & Co.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fifth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Retractable Techs., Inc. v. Becton Dickinson & Co., 919 F.3d 869 (5th Cir. 2019).

Opinion

PATRICK E. HIGGINBOTHAM, Circuit Judge:

A jury found that Becton Dickinson & Co. falsely advertised its products for years. The district court determined that neither disgorgement of profits nor further injunctive relief would be equitable under the circumstances. It did not abuse its discretion. We affirm.

I

This case involves a narrow subset of medical syringes: retractable syringes, a type of "safety syringe" designed to reduce risk of accidental needlesticks. Retractable syringes compete both with other varieties of safety syringes and with "conventional" syringes. 1 Although retractable syringes provide significant protection against accidents, their fixed needles prevent use for some hospital and clinical purposes. 2

*873 Retractable Technologies, Inc. and Becton Dickinson & Co. compete in the U.S. safety syringe market alongside two other major safety syringe manufacturers. 3 RTI primarily manufactures retractable syringes and dominates the retractable syringe sub-market; while BD produces retractable syringes, it also produces several conventional and non-retractable safety products that account for the bulk of its revenue. 4 This appeal is the latest stage of ongoing litigation between the two.

A

BD made two false claims in its marketing materials. First, it advertised itself as having the "world's sharpest needle," reflecting that needle sharpness is seen as a proxy for patient comfort, and persisted in doing so after its internal tests indicated otherwise. 5 Second, it promoted its retractable syringes as having seven times less "waste space" than RTI's product, meaning that the syringes would waste less medicine per use. 6 While BD's testing supported this claim at first, internal tests from 2003 onward demonstrated that RTI's syringes were less wasteful than claimed. 7

RTI and its founder, Thomas J. Shaw, sued BD for antitrust violations and false advertising under the Lanham Act, pointing to these false claims and other allegedly unfair and anticompetitive business practices. 8 A jury sided with RTI on one of its antitrust claims and all of its Lanham Act false advertising claims. It found that RTI was due more than $ 113.5 million in antitrust damages. 9 RTI elected to not seek an award of damages for the Lanham Act claim from the jury. 10

The district court statutorily trebled the antitrust damages and granted attorney's fees, resulting in a total award of approximately $ 352 million. RTI additionally requested disgorgement of BD's profits and injunctive relief. The district court concluded that equity favored disgorgement, but that any relevant profits were subsumed by the trebled antitrust damages award. It also crafted a six-part injunction requiring BD to cease certain advertising claims for several years, post a notice on its website, notify various entities of the false claims, and implement a training program for employees and distributors. 11 On BD's motion to stay the injunction pending appeal, the district court stayed only the portion of the injunction that would require BD to notify its "end users"-that is, the "hospitals, clinics, and other healthcare providers that do not resell the syringes in the ordinary course of business." 12

*874 B

While BD began to comply with the portions of the injunction that were not stayed, it appealed the jury's finding of antitrust liability and the district court's remedies determination. 13 We concluded that RTI's antitrust claim was legally insufficient and reversed that portion of the judgment-so at a minimum, RTI was no longer entitled to trebled antitrust damages and attorney's fees. 14 Having determined that the injunction was predicated at least in part on BD's antitrust liability, we also vacated the injunction and remanded to the district court to determine whether the Lanham Act violations standing alone justified continued equitable relief. 15

As for disgorgement of BD's profits, we specifically approved of some of the district court's findings: "at least some portion of BD's profits were attributable to the false advertising," BD intended to confuse or deceive consumers, and RTI did not unreasonably delay in seeking relief. 16 Beyond that, recognizing that the district court had subsumed the disgorgement into the trebled antitrust damages, we remanded "for a thorough reweighing of the remaining factors and the entirety of the record to determine whether and how much profit BD should disgorge to compensate for the Lanham Act violations." 17 "In particular," we observed, "when assessing [whether BD diverted sales from RTI], the district court should bear in mind that speculative and attenuated evidence of diversion of sales will not suffice." 18

On remand, the district court conducted a one-day bench trial and evaluated an otherwise closed record. It ultimately declined to disgorge BD's profits or reinstate any portion of the vacated injunction. RTI appeals.

II

We review a district court's decision to grant or withhold disgorgement or injunctive relief under the Lanham Act for abuse of discretion. 19 Exercise of its discretion must not have been based on an "erroneous view of the law" or a "clearly erroneous assessment of the evidence." 20 The district court otherwise has "[g]reat latitude" 21 to "determine the nature of the infringing conduct and its adverse effects, *875 if any, on the plaintiff," and to fashion relief accordingly. 22

III

We will begin with the district court's denial of further injunctive relief. A district court's discretion to grant injunctive relief is both broad and constrained by well-settled principles.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
919 F.3d 869, Counsel Stack Legal Research, https://law.counselstack.com/opinion/retractable-techs-inc-v-becton-dickinson-co-ca5-2019.